Serina Therapeutics (SER) Research & Development (2018 - 2026)

Serina Therapeutics has disclosed Research & Development across 9 years of filings, most recently posting $3.8 million for Q2 2026.

• In Q2 2026, Research & Development rose 21.07% year-over-year to $3.8 million; the TTM figure through Jun 2026 stood at $14.0 million (up 28.82% YoY), while the FY2025 annual figure was $13.2 million, up 75.87% from the prior year.
• Research & Development came in at $3.8 million for Q2 2026 at Serina Therapeutics, up from $3.4 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $3.8 million in Q2 2026 to a low of $162000.0 in Q3 2022.
• Average Research & Development over 5 years is $1.6 million, with a median of $1.1 million recorded in 2024.
• Year-over-year, Research & Development sank 46.15% in 2022 and jumped 336.06% in 2023.
• Over 5 years, Research & Development stood at $208000.0 in 2022, then soared by 336.06% to $907000.0 in 2023, then surged by 160.75% to $2.4 million in 2024, then jumped by 43.81% to $3.4 million in 2025, then gained by 12.2% to $3.8 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $3.8 million in Q2 2026, $3.4 million in Q4 2025, and $3.7 million in Q3 2025.